NGI is a leading provider of nucleic acid screening services to the global biotechnology industry and screens millions of plasma donations a year for blood borne infectious agents. A key advantage of our testing platform is the ability to robustly detect nucleic acid targets in pools of up to 512 specimens using highly sensitive assays. Specimen pooling substantially reduces the cost of nucleic acid testing over systems that test a single sample at a time.
Specimen pools are generated using an automated liquid handling system and proprietary pooling algorithms. Master pools are tested and cleared if results are negative. Positive pools are resolved using proprietary algorithms and the suspected positive specimen(s) are tested individually to confirm the presence of nucleic acid target.
Our Screening Services include:
- Screening of a diverse set of specimen types including blood, plasma, saliva, tissue culture, and peripheral blood mononuclear cells using our validated assays
- Development and validation of assays for emerging pathogens, pathogen variants, or other non-pathogenic nucleic acid targets for broad-based screening applications
- An experienced and client focused services team
Contact NGI to find out how we can develop customized solutions for your screening needs.
|Documents and References|
|Certifications and Licenses|